Literature DB >> 2334149

Disposition of roxithromycin in patients with normal and severely impaired renal function.

C E Halstenson1, J A Opsahl, M H Schwenk, J M Kovarik, S K Puri, I Ho, G R Matzke.   

Abstract

The disposition of roxithromycin, an investigational macrolide antibiotic, was evaluated in 20 subjects, 10 with normal renal function (creatinine clearance [CLCR] of 116 +/- 17 ml/min [mean +/- standard deviation]) and 10 with severely impaired renal function (CLCR of 10.2 +/- 2.6 ml/min) after a single 300-mg oral dose. Plasma concentration-time data were analyzed in terms of a one- or two-compartment oral absorption model utilizing nonlinear regression analysis. The terminal elimination half-life was significantly prolonged in the group with severely impaired renal function (15.5 +/- 4.7 h) compared with that of the group with normal renal function (7.9 +/- 2.5 h). Apparent total body clearance was significantly reduced in the renally impaired (25.3 +/- 10.5 ml/min) in relation to the group with normal renal function (48.8 +/- 11.1 ml/min). The first-order absorption rate constants and apparent volumes of distribution did not differ between the two groups. These data indicate that the disposition of roxithromycin is significantly delayed in subjects with CLCRs of less than 15 ml/min and suggest that the roxithromycin dosing interval be doubled for these patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2334149      PMCID: PMC171601          DOI: 10.1128/AAC.34.3.385

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

2.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 3.  Roxithromycin: a pharmacokinetic review of a macrolide.

Authors:  S K Puri; H B Lassman
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

Review 4.  Renal disease and drug metabolism: an overview.

Authors:  T P Gibson
Journal:  Am J Kidney Dis       Date:  1986-07       Impact factor: 8.860

5.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.

Authors:  G R Matzke; P A Abraham; C E Halstenson; W F Keane
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

7.  Pharmacokinetics of intravenous erythromycin.

Authors:  P G Welling; W A Craig
Journal:  J Pharm Sci       Date:  1978-08       Impact factor: 3.534

8.  Hearing loss and erythromycin pharmacokinetics in a patient receiving hemodialysis.

Authors:  P D Kroboth; M A McNeil; A Kreeger; J Dominguez; R Rault
Journal:  Arch Intern Med       Date:  1983-06

9.  Changes in erythromycin pharmacokinetics induced by renal failure.

Authors:  A Kanfer; G Stamatakis; J C Torlotin; G Fredj; S Kenouch; J P Méry
Journal:  Clin Nephrol       Date:  1987-03       Impact factor: 0.975

10.  Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.

Authors:  D B Haughey; C J Kraft; G R Matzke; W F Keane; C E Halstenson
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

View more
  4 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part I).

Authors:  J P Fillastre; E Singlas
Journal:  Clin Pharmacokinet       Date:  1991-04       Impact factor: 6.447

2.  Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice.

Authors:  R H Gelber; P Siu; M Tsang; L P Murray
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Principles of drug administration in renal insufficiency.

Authors:  Y W Lam; S Banerji; C Hatfield; R L Talbert
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

4.  Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding.

Authors:  Michael J Dolton; David Z D'Argenio
Journal:  J Antimicrob Chemother       Date:  2017-04-01       Impact factor: 5.790

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.